Candel Therapeutics, Inc. (CADL) Misses Q4 EPS by 29c
Tweet
Share
E-mailGet Alerts CADL Hot Sheet
Join SI Premium – FREE
Candel Therapeutics, Inc. (NASDAQ: CADL) reported Q4 EPS of ($0.54), $0.29 worse than the analyst estimate of ($0.25).
For earnings history and earnings-related data on Candel Therapeutics, Inc. (CADL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- NIO Inc. (NIO) Tops Q2 EPS by 33c; offers guidance
- Hyperscale Data reports blockchain revenue surge in Q2 2026
- Stifel Starts Tower Semiconductor (TSEM) at Buy, Top Pick
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
